| Details
|
| UPD |
sitematrix Changed from 0 to
|
19/04/2024 09:11:30
(LoweryM )
|
| UPD |
Olaparib (Lynparza®) avastin removed
|
19/04/2024 09:11:30
(LoweryM )
|
| UPD |
sitematrix Changed from 0 to
|
19/04/2024 09:10:58
(LoweryM )
|
| UPD |
FurtherInformation Changed from
- Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based&
|
19/04/2024 09:10:58
(LoweryM )
|
| UPD |
Olaparib (Lynparza®) maintenance added (TA946)
|
19/04/2024 09:10:58
(LoweryM )
|
| LDL |
Link Added : NICE TA946: Olaparib with bevacizumab for maintenance treatment of advanced high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer : https://www.nice.org.uk/guidance/ta946
|
17/04/2024 10:59:19
(DavidS )
|
| UPD |
sitematrix Changed from 0 to
|
17/04/2024 10:58:56
(DavidS )
|
| UPD |
isDraft Changed from N to Y
|
17/04/2024 10:58:56
(DavidS )
|
| UPD |
FurtherInformation Changed from
- Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based&
|
17/04/2024 10:58:56
(DavidS )
|
| UPD |
Olaparib (Lynparza®) NICE TA946
|
17/04/2024 10:58:56
(DavidS )
|
| UPD |
Published from Draft Mode
|
18/01/2024 10:33:01
(LoweryM )
|
| UPD |
sitematrix Changed from 0 to
|
12/01/2024 13:50:42
(DavidS )
|
| UPD |
isDraft Changed from N to Y
|
12/01/2024 13:50:42
(DavidS )
|
| UPD |
FurtherInformation Changed from
- Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based&
|
12/01/2024 13:50:42
(DavidS )
|
| UPD |
Olaparib (Lynparza®) NHSE SSC2566
|
12/01/2024 13:50:42
(DavidS )
|
| UPD |
Published from Draft Mode
|
20/11/2023 16:33:47
(LoweryM )
|
| LDL |
Link Added : NICE TA908: Olaparib for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy : https://www.nice.org.uk/guidance/ta908
|
20/11/2023 13:21:54
(DavidS )
|
| UPD |
sitematrix Changed from 0 to
|
20/11/2023 13:21:33
(DavidS )
|
| UPD |
isDraft Changed from N to Y
|
20/11/2023 13:21:33
(DavidS )
|
| UPD |
FurtherInformation Changed from
- Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based&
|
20/11/2023 13:21:33
(DavidS )
|
| UPD |
Olaparib (Lynparza®) NICE TA908
|
20/11/2023 13:21:33
(DavidS )
|
| UPD |
Published from Draft Mode
|
10/10/2023 16:13:26
(LoweryM )
|
| UPD |
sitematrix Changed from 0 to
|
10/10/2023 15:12:54
(DavidS )
|
| UPD |
Olaparib (Lynparza®) addition of brand name
|
10/10/2023 15:12:54
(DavidS )
|
| UPD |
sitematrix Changed from 0 to
|
10/10/2023 13:48:04
(DavidS )
|
| UPD |
FurtherInformation Changed from
- Approved for the maintenance treatment of BRCA 1 or 2 mutated, relapsed, platinum-sensitive ovarian, fallopian tube and peritoneal cancer in people whose relapsed disease has responded to platinum-based&
|
10/10/2023 13:48:04
(DavidS )
|
| UPD |
Olaparib NICE TA887
|
10/10/2023 13:48:04
(DavidS )
|
| LDL |
Link Added : NICE TA887: Olaparib for previously treated BRCA mutation-positive hormone-relapsed metastatic prostate cancer : https://www.nice.org.uk/guidance/ta887
|
10/10/2023 13:47:36
(DavidS )
|
| UPD |
sitematrix Changed from 0 to
|
10/10/2023 13:46:27
(DavidS )
|
| UPD |
isDraft Changed from N to Y
|
10/10/2023 13:46:27
(DavidS )
|
